A Phase I Dose Escalation Study of the Combination of Lenalidomide (Revlimid), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing from Stable Disease with Multiple Myeloma

Trial Profile

A Phase I Dose Escalation Study of the Combination of Lenalidomide (Revlimid), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing from Stable Disease with Multiple Myeloma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Sep 2015

At a glance

  • Drugs Lenalidomide (Primary) ; Cyclophosphamide; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 30 Jan 2014 Accrual to date is 103% according to United Kingdom Clinical Research Network
    • 21 Jul 2009 Trial phase changed from I/II to I as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top